Elevance Health (ELV) Set to Announce Quarterly Earnings on Wednesday

Key Points

• Elevance Health is expected to report Q3 2026 earnings before the market opens on October 21. Analysts project earnings of $4.70 per share on $49.29 billion in revenue, with the conference call scheduled for 8:30 a.m. ET.
• In its previous quarter, Elevance reported $7.45 EPS and $49.83 billion in revenue, exceeding analyst estimates; revenue increased 0.8% year over year.
• Analysts maintain a “Moderate Buy” consensus rating, with 15 Buy ratings and 8 Holds and an average price target of $441.71. Shares recently opened at $425.53, near their 52-week high of $436.24.

Elevance Health (NYSE:ELV - Get Free Report) is projected to release its Q3 2026 results before the market opens on Wednesday, October 21st. Analysts expect Elevance Health to post earnings of $4.70 per share and revenue of $49.29 billion for the quarter. Individuals can find conference call details on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 21, 2026 at 8:30 AM ET.

Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings results on Wednesday, July 15th. The company reported $7.45 EPS for the quarter, beating the consensus estimate of $6.21 by $1.24. The firm had revenue of $49.83 billion during the quarter, compared to the consensus estimate of $48.88 billion. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. Elevance Health's revenue for the quarter was up .8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $8.84 EPS. On average, analysts expect Elevance Health to post $27.22 EPS for the current fiscal year and $29.45 EPS for the next fiscal year.

Elevance Health Stock Up 0.8%

Shares of NYSE:ELV opened at $425.53 on Wednesday. The stock has a market cap of $92.28 billion, a P/E ratio of 14.36, a P/E/G ratio of 2.19 and a beta of 0.70. The firm has a fifty day moving average price of $402.02 and a 200 day moving average price of $383.66. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.52 and a quick ratio of 1.52. Elevance Health has a 1-year low of $274.84 and a 1-year high of $436.24.

Analyst Upgrades and Downgrades

A number of research analysts have commented on ELV shares. Raymond James Financial set a $450.00 price objective on shares of Elevance Health in a research note on Tuesday, July 7th. Sanford C. Bernstein set a $488.00 target price on shares of Elevance Health in a research note on Thursday, July 16th. Robert W. Baird boosted their price target on Elevance Health from $331.00 to $393.00 and gave the company a "neutral" rating in a research report on Thursday, July 16th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $395.00 price objective on shares of Elevance Health in a research note on Thursday, July 16th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Elevance Health in a research note on Thursday, August 13th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $441.71.

About Elevance Health

Elevance Health, Inc NYSE: ELV is a health benefits and services company that provides health insurance, managed care and related healthcare solutions in the United States. Its offerings serve individuals, employers, government-sponsored programs and other organizations across commercial, Medicare and Medicaid markets.

The company operates a portfolio of health plans, including Blue Cross Blue Shield-affiliated plans in several states, as well as government-focused plans marketed under brands such as Wellpoint.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.